Moderna shares double to $140.19 as cancer vaccine data revives investor optimism
AI Market Summary
Positive late-stage data for Moderna's mRNA cancer vaccine (with Merck's Keytruda) drove a sharp repricing in growth expectations, lifting shares on heavy volume and pushing Merck to a record high. Upward revisions to 2032 sales potential reinforce the longer-term revenue diversification narrative beyond COVID-19. Elevated short interest (13.5% of free float) adds squeeze dynamics, amplifying near-term volatility and momentum.
Impact level
● Medium
Affected assets
NCSKMRNA2USD/USDT+4.65%
AI Insight · NCSKMRNA2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Moderna shares doubled to a two-year high of $140.19, adding about $30 billion in market value in a single session as trading volume surged to more than 15 times the 50-day average. Merck rose 10% to a record high. Leerink Partners lifted its 2032 sales outlook for the cancer vaccine therapy to $1.4 billion from up to $1.2 billion. ORTEX data show short interest in Moderna at 13.5% of the free float, and analysts said growing pressure on short sellers is increasing the risk of a squeeze.
